Yingqi Tang

Prof. Yingqi Tang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2022 in Small Science
Verified
Journal Article
Open access
HJHongyue Jing
Hongyue Jing
BLBenzheng Lyu
Benzheng Lyu
YTYingqi Tang
Yingqi Tang
SBSungpyo Baek
Sungpyo Baek
JPJin-Hong Park
Jin-Hong Park
SLSungjoo Lee
Sungjoo Lee
The oxidation degradation by unsaturated metal atoms or dangling bonds at MXene edges and defects severely hinders the practical application of MXene. Herein, a passivation scheme for Ti3C2Tx MXene is demonstrated by utilizing a sulfhydryl‐containing molecule, β‐mercaptoethanol (BME), which can significantly suppress the Ti3C2Tx oxidation in various environments, including long‐term storage of Ti3C2Tx aqueous dispersions (2 m), single‐layer Ti3C2Tx‐based devices in humid air (2 m), and high‐temperature environment (12 h). Notably, the nonionic BME does not cause aggregation but maintains the 2D morphology of Ti3C2Tx. A comprehensive investigation of the protection mechanism through density functional theory (DFT) calculations and experimental characterizations reveals that BME is adsorbed especially at the edges and surface defects of MXene (binding energy −1.70 and −1.05 eV), where the degradation starts. Further, the electron‐donating effect of sulfhydryl groups tunes the work function of Ti3C2Tx from 4.70 to 4.39 eV, resulting in improved carrier‐transport performances in MoS2 field‐effect transistors owing to band alignment, where BME–Ti3C2Tx serves as the source electrode. The described methodology can largely contribute to the ultralong service life of 2D Ti3C2Tx without affecting its excellent properties, thereby promoting the practical application of this emerging material.

1 February 2025 in Integrative Cancer Therapies
Verified
Journal Article
Open access
JYJie Yu
Jie Yu
FJFeng Jin
Feng Jin
YTYingqi Tang
Yingqi Tang
YHYumin Huang
Yumin Huang
Background: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Many researchers have previously reported that natural compounds from plants or Chinese Traditional Herbs have a potential to treat NSCLC. But it has not been reported that phytol can treat NSCLC. In this research, we first exposed this effect on A549 cells and researched the mechanism. Methods: In order to evaluate whether phytol has a role in human NSCLC, a human non-tumoral bronchial epithelial cell line (NL20), adenocarcinomic human alveolar basal epithelial (A549) cell line, and NCI-H69 SCLC (H69) cell line were used for related experiments. After determining that phytol had no toxicity to NL20 cells, A549 cells, or H69 cells, the inhibitory effect of phytol on cancer cell related characteristics of cells were determined by luciferase assay, QRT-PCR, proliferation, invasion, and would healing cellular response experiments. Additionally, the quantification of apoptotic cells has been achieved through flow cytometry. Then, bioinformatics was used to establish a database to screen and speculate on phytol’s corresponding targets in lung cancer. Finally, immunoblotting experiments were used to determine the specific pathways affected by phytol. Results: Treatment with phytol at concentrations ranging from 0 to 80 µM for 24 hours was not cytotoxic to the A549 cells and H69 cells. Phytol inhibited AP-1-mediated and NF-κB-mediated luciferase activity in a dose-dependent manner in A549 cells, but not H69 cells. Additionally, phytol significantly inhibited the levels of MMP9, IL-6, VEGFA, IL-8, and NFKBIA in A549 cells, but had no significant effects on H69 cells. Phytol induced significant dose-dependent growth inhibitory effects on A549 cells. A significant decrease in colony formation and migration was observed. Bioinformatic and immunoblotting analysis indicated that phytol inhibited proliferation and migration of A549 cells through the PI3K-Akt signaling pathway. Conclusions: Phytol exhibits anticancer activity by inhibiting PI3K-Akt signaling pathway and may be applicable in the clinical prevention and treatment of lung cancer in the future.

20 July 2023 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
YTYingqi Tang
Yingqi Tang
NLNannan Li
Nannan Li
HLHao Li
Hao Li
HLHai Li
Hai Li
JLJin Yong Lee
Jin Yong Lee